{"id":"https://openalex.org/W4400875840","doi":"https://doi.org/10.1124/dmd.124.001841","title":"Metabolism and Excretion of [14C]Mobocertinib, a Selective Covalent Inhibitor of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations, in Healthy Male Subjects","display_name":"Metabolism and Excretion of [14C]Mobocertinib, a Selective Covalent Inhibitor of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations, in Healthy Male Subjects","publication_year":2024,"publication_date":"2024-07-22","ids":{"openalex":"https://openalex.org/W4400875840","doi":"https://doi.org/10.1124/dmd.124.001841","pmid":"https://pubmed.ncbi.nlm.nih.gov/39038951"},"language":"en","primary_location":{"id":"doi:10.1124/dmd.124.001841","doi":"https://doi.org/10.1124/dmd.124.001841","is_oa":true,"landing_page_url":"https://doi.org/10.1124/dmd.124.001841","pdf_url":null,"source":{"id":"https://openalex.org/S145039780","display_name":"Drug Metabolism and Disposition","issn_l":"0090-9556","issn":["0090-9556","1521-009X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310316283","host_organization_name":"American Society for Pharmacology and Experimental Therapeutics","host_organization_lineage":["https://openalex.org/P4310316283"],"host_organization_lineage_names":["American Society for Pharmacology and Experimental Therapeutics"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Metabolism and Disposition","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1124/dmd.124.001841","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Hao Chen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140176","display_name":"Takeda (United States)","ror":"https://ror.org/03bygaq51","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hao Chen","raw_affiliation_strings":["Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (H.C., A.S., S.K., R.G., S.P., L.C., Y.L., S.K.C., S.X.Z.); and Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (S.Z.)","Takeda Development Center Americas Inc., United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (H.C., A.S., S.K., R.G., S.P., L.C., Y.L., S.K.C., S.X.Z.); and Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (S.Z.)","institution_ids":["https://openalex.org/I4210140176"]},{"raw_affiliation_string":"Takeda Development Center Americas Inc., United States","institution_ids":["https://openalex.org/I4210140176"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Abhi Shah","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140176","display_name":"Takeda (United States)","ror":"https://ror.org/03bygaq51","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Abhi Shah","raw_affiliation_strings":["Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (H.C., A.S., S.K., R.G., S.P., L.C., Y.L., S.K.C., S.X.Z.); and Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (S.Z.)","DMPK/BioAnalytical, PepGen, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (H.C., A.S., S.K., R.G., S.P., L.C., Y.L., S.K.C., S.X.Z.); and Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (S.Z.)","institution_ids":["https://openalex.org/I4210140176"]},{"raw_affiliation_string":"DMPK/BioAnalytical, PepGen, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071162794","display_name":"Suguru Kato","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140176","display_name":"Takeda (United States)","ror":"https://ror.org/03bygaq51","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I44892455"]},{"id":"https://openalex.org/I4405254473","display_name":"Chugai Pharmaceutical Co., Ltd. (Japan)","ror":"https://ror.org/01v743b94","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405254473"]}],"countries":["JP","US"],"is_corresponding":false,"raw_author_name":"Suguru Kato","raw_affiliation_strings":["Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (H.C., A.S., S.K., R.G., S.P., L.C., Y.L., S.K.C., S.X.Z.); and Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (S.Z.)","Quality Development Department, Chugai Pharmaceuticals Co., Ltd., Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (H.C., A.S., S.K., R.G., S.P., L.C., Y.L., S.K.C., S.X.Z.); and Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (S.Z.)","institution_ids":["https://openalex.org/I4210140176"]},{"raw_affiliation_string":"Quality Development Department, Chugai Pharmaceuticals Co., Ltd., Japan","institution_ids":["https://openalex.org/I4405254473"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101810888","display_name":"Robert Griffin","orcid":"https://orcid.org/0000-0002-1907-2421","observed_orcids":["https://orcid.org/0000-0002-1907-2421"]},"institutions":[{"id":"https://openalex.org/I4210140176","display_name":"Takeda (United States)","ror":"https://ror.org/03bygaq51","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert Griffin","raw_affiliation_strings":["Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (H.C., A.S., S.K., R.G., S.P., L.C., Y.L., S.K.C., S.X.Z.); and Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (S.Z.)","Takeda Development Center Americas Inc, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (H.C., A.S., S.K., R.G., S.P., L.C., Y.L., S.K.C., S.X.Z.); and Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (S.Z.)","institution_ids":["https://openalex.org/I4210140176"]},{"raw_affiliation_string":"Takeda Development Center Americas Inc, United States","institution_ids":["https://openalex.org/I4210140176"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018361694","display_name":"Steven Zhang","orcid":"https://orcid.org/0009-0001-9062-3978","observed_orcids":["https://orcid.org/0009-0001-9062-3978","https://orcid.org/0000-0001-6583-6771"]},"institutions":[{"id":"https://openalex.org/I4210106615","display_name":"Novo Nordisk (United States)","ror":"https://ror.org/011y67d23","country_code":"US","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210106615","https://openalex.org/I4210159963"]},{"id":"https://openalex.org/I4210140176","display_name":"Takeda (United States)","ror":"https://ror.org/03bygaq51","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven Zhang","raw_affiliation_strings":["Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (H.C., A.S., S.K., R.G., S.P., L.C., Y.L., S.K.C., S.X.Z.); and Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (S.Z.)","Novo Nordisk Pharmaceuticals, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (H.C., A.S., S.K., R.G., S.P., L.C., Y.L., S.K.C., S.X.Z.); and Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (S.Z.)","institution_ids":["https://openalex.org/I4210140176"]},{"raw_affiliation_string":"Novo Nordisk Pharmaceuticals, United States","institution_ids":["https://openalex.org/I4210106615"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046740192","display_name":"Sandeepraj Pusalkar","orcid":"https://orcid.org/0000-0002-6916-5669","observed_orcids":["https://orcid.org/0000-0002-6916-5669"]},"institutions":[{"id":"https://openalex.org/I4210140176","display_name":"Takeda (United States)","ror":"https://ror.org/03bygaq51","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sandeepraj Pusalkar","raw_affiliation_strings":["Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (H.C., A.S., S.K., R.G., S.P., L.C., Y.L., S.K.C., S.X.Z.); and Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (S.Z.)","Servier Bioinnovation LLC, United States"],"raw_orcid":"https://orcid.org/0000-0002-6916-5669","affiliations":[{"raw_affiliation_string":"Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (H.C., A.S., S.K., R.G., S.P., L.C., Y.L., S.K.C., S.X.Z.); and Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (S.Z.)","institution_ids":["https://openalex.org/I4210140176"]},{"raw_affiliation_string":"Servier Bioinnovation LLC, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Lawrence Cohen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140176","display_name":"Takeda (United States)","ror":"https://ror.org/03bygaq51","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lawrence Cohen","raw_affiliation_strings":["Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (H.C., A.S., S.K., R.G., S.P., L.C., Y.L., S.K.C., S.X.Z.); and Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (S.Z.)","Takeda Pharmaceuticals, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (H.C., A.S., S.K., R.G., S.P., L.C., Y.L., S.K.C., S.X.Z.); and Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (S.Z.)","institution_ids":["https://openalex.org/I4210140176"]},{"raw_affiliation_string":"Takeda Pharmaceuticals, United States","institution_ids":["https://openalex.org/I4210140176"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102995201","display_name":"Yuexian Li","orcid":"https://orcid.org/0000-0002-4804-119X","observed_orcids":["https://orcid.org/0000-0002-4804-119X"]},"institutions":[{"id":"https://openalex.org/I4210140176","display_name":"Takeda (United States)","ror":"https://ror.org/03bygaq51","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yuexian Li","raw_affiliation_strings":["Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (H.C., A.S., S.K., R.G., S.P., L.C., Y.L., S.K.C., S.X.Z.); and Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (S.Z.)","Takeda Development Center Americas, Inc, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (H.C., A.S., S.K., R.G., S.P., L.C., Y.L., S.K.C., S.X.Z.); and Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (S.Z.)","institution_ids":["https://openalex.org/I4210140176"]},{"raw_affiliation_string":"Takeda Development Center Americas, Inc, United States","institution_ids":["https://openalex.org/I4210140176"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101406225","display_name":"Swapan K. Chowdhury","orcid":"https://orcid.org/0000-0003-4004-8925","observed_orcids":["https://orcid.org/0000-0003-4004-8925"]},"institutions":[{"id":"https://openalex.org/I4210140176","display_name":"Takeda (United States)","ror":"https://ror.org/03bygaq51","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I44892455"]},{"id":"https://openalex.org/I4405270318","display_name":"Boston Pharmaceuticals (United States)","ror":"https://ror.org/00fk46e73","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270318"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Swapan K. Chowdhury","raw_affiliation_strings":["Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (H.C., A.S., S.K., R.G., S.P., L.C., Y.L., S.K.C., S.X.Z.); and Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (S.Z.)","Boston Pharmaceuticals, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (H.C., A.S., S.K., R.G., S.P., L.C., Y.L., S.K.C., S.X.Z.); and Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (S.Z.)","institution_ids":["https://openalex.org/I4210140176"]},{"raw_affiliation_string":"Boston Pharmaceuticals, United States","institution_ids":["https://openalex.org/I4405270318"]}]},{"author_position":"last","author":{"id":null,"display_name":"Sean Xiaochun Zhu","orcid":"https://orcid.org/0009-0006-7937-812X","observed_orcids":["https://orcid.org/0009-0006-7937-812X"]},"institutions":[{"id":"https://openalex.org/I4210140176","display_name":"Takeda (United States)","ror":"https://ror.org/03bygaq51","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sean Xiaochun Zhu","raw_affiliation_strings":["Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (H.C., A.S., S.K., R.G., S.P., L.C., Y.L., S.K.C., S.X.Z.); and Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (S.Z.) xiaochun.zhu@takeda.com","DMPK, Takeda Pharmaceuticals, United States"],"raw_orcid":"https://orcid.org/0009-0006-7937-812X","affiliations":[{"raw_affiliation_string":"Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (H.C., A.S., S.K., R.G., S.P., L.C., Y.L., S.K.C., S.X.Z.); and Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc., Cambridge, Massachusetts (S.Z.) xiaochun.zhu@takeda.com","institution_ids":["https://openalex.org/I4210140176"]},{"raw_affiliation_string":"DMPK, Takeda Pharmaceuticals, United States","institution_ids":["https://openalex.org/I4210140176"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3500,"currency":"USD","value_usd":3500},"apc_paid":{"value":3500,"currency":"USD","value_usd":3500},"fwci":1.8518,"has_fulltext":false,"cited_by_count":8,"citation_normalized_percentile":{"value":0.82057294,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":96,"max":98},"biblio":{"volume":"52","issue":"10","first_page":"1115","last_page":"1123"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9746000170707703,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9746000170707703,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.015399999916553497,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.0010999999940395355,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mobocertinib","display_name":"mobocertinib","score":1.0},{"id":"https://openalex.org/keywords/egfr-exon-20-insertion-mutation","display_name":"EGFR exon 20 insertion","score":0.9139999747276306},{"id":"https://openalex.org/keywords/drug-metabolism","display_name":"drug metabolism","score":0.8349999785423279},{"id":"https://openalex.org/keywords/drug-excretion","display_name":"drug excretion","score":0.7889999747276306},{"id":"https://openalex.org/keywords/first-pass-metabolism","display_name":"first-pass metabolism","score":0.734000027179718},{"id":"https://openalex.org/keywords/cyp3a4-5","display_name":"CYP3A4/5","score":0.8889999985694885},{"id":"https://openalex.org/keywords/oxidative-metabolism","display_name":"oxidative metabolism","score":0.8330000042915344},{"id":"https://openalex.org/keywords/plasma-protein-binding","display_name":"plasma protein binding","score":0.8090000152587891},{"id":"https://openalex.org/keywords/human-serum-albumin","display_name":"human serum albumin","score":0.9520000219345093},{"id":"https://openalex.org/keywords/fecal-excretion","display_name":"fecal excretion","score":0.8799999952316284},{"id":"https://openalex.org/keywords/cysteine-conjugation","display_name":"cysteine conjugation","score":0.9269999861717224},{"id":"https://openalex.org/keywords/renal-excretion","display_name":"renal excretion","score":0.906000018119812}],"concepts":[{"id":"https://openalex.org/C143065580","wikidata":"https://www.wikidata.org/wiki/Q3285695","display_name":"Mutant","level":3,"score":0.7064120173454285},{"id":"https://openalex.org/C62231903","wikidata":"https://www.wikidata.org/wiki/Q1057","display_name":"Metabolism","level":2,"score":0.7038829326629639},{"id":"https://openalex.org/C10146269","wikidata":"https://www.wikidata.org/wiki/Q185557","display_name":"Excretion","level":2,"score":0.5555112957954407},{"id":"https://openalex.org/C36823959","wikidata":"https://www.wikidata.org/wiki/Q373027","display_name":"Exon","level":3,"score":0.547491729259491},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.5083622336387634},{"id":"https://openalex.org/C180577832","wikidata":"https://www.wikidata.org/wiki/Q127920","display_name":"Covalent bond","level":2,"score":0.47067102789878845},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.4025760591030121},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.37032103538513184},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.34666571021080017},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.33913755416870117},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3342720866203308},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.25917986035346985},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.17976948618888855},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000814","descriptor_name":"Aniline Compounds","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002250","descriptor_name":"Carbon Radioisotopes","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005091","descriptor_name":"Exons","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005243","descriptor_name":"Feces","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016254","descriptor_name":"Mutagenesis, Insertional","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D064368","descriptor_name":"Healthy Volunteers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1124/dmd.124.001841","doi":"https://doi.org/10.1124/dmd.124.001841","is_oa":true,"landing_page_url":"https://doi.org/10.1124/dmd.124.001841","pdf_url":null,"source":{"id":"https://openalex.org/S145039780","display_name":"Drug Metabolism and Disposition","issn_l":"0090-9556","issn":["0090-9556","1521-009X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310316283","host_organization_name":"American Society for Pharmacology and Experimental Therapeutics","host_organization_lineage":["https://openalex.org/P4310316283"],"host_organization_lineage_names":["American Society for Pharmacology and Experimental Therapeutics"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Metabolism and Disposition","raw_type":"journal-article"},{"id":"pmid:39038951","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/39038951","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug metabolism and disposition: the biological fate of chemicals","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1124/dmd.124.001841","doi":"https://doi.org/10.1124/dmd.124.001841","is_oa":true,"landing_page_url":"https://doi.org/10.1124/dmd.124.001841","pdf_url":null,"source":{"id":"https://openalex.org/S145039780","display_name":"Drug Metabolism and Disposition","issn_l":"0090-9556","issn":["0090-9556","1521-009X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310316283","host_organization_name":"American Society for Pharmacology and Experimental Therapeutics","host_organization_lineage":["https://openalex.org/P4310316283"],"host_organization_lineage_names":["American Society for Pharmacology and Experimental Therapeutics"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Metabolism and Disposition","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9391000270843506,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":22,"referenced_works":["https://openalex.org/W1990938178","https://openalex.org/W2069456709","https://openalex.org/W2143863753","https://openalex.org/W2151016309","https://openalex.org/W2471422459","https://openalex.org/W2901139388","https://openalex.org/W2920175805","https://openalex.org/W3044159365","https://openalex.org/W3085622155","https://openalex.org/W3129535020","https://openalex.org/W3132930574","https://openalex.org/W3169194151","https://openalex.org/W3185544520","https://openalex.org/W3187778387","https://openalex.org/W3217464049","https://openalex.org/W4281735195","https://openalex.org/W4281739620","https://openalex.org/W4286715803","https://openalex.org/W4294591628","https://openalex.org/W4296025800","https://openalex.org/W4389280218","https://openalex.org/W4398770614"],"related_works":["https://openalex.org/W4398770614","https://openalex.org/W2163607253","https://openalex.org/W2899115689","https://openalex.org/W3169194151","https://openalex.org/W4406132544","https://openalex.org/W1997320918","https://openalex.org/W3157551671","https://openalex.org/W4406480810","https://openalex.org/W3087430279","https://openalex.org/W2157975224"],"abstract_inverted_index":{"Mobocertinib":[0,42,103,130,188,210],"(formerly":[1],"known":[2],"as":[3,53],"TAK-788)":[4],"is":[5],"a":[6,36,138,174,182],"targeted":[7,175],"covalent":[8,176],"tyrosine":[9],"kinase":[10],"inhibitor":[11,177],"of":[12,29,40,61,85,95,101,111,122,140,161,173,186,202,226],"epidermal":[13],"growth":[14],"factor":[15],"receptor":[16],"with":[17,108,137],"exon":[18],"20":[19],"insertion":[20],"mutations.":[21],"This":[22,166],"article":[23],"describes":[24,168],"the":[25,78,92,109,112,126,169,227],"metabolism":[26,107,136,154,170,218],"and":[27,158,171],"excretion":[28,121,160,172,222],"mobocertinib":[30,76,123,178],"in":[31,91,179,207],"healthy":[32],"male":[33],"subjects":[34],"after":[35,181,223],"single":[37,183],"oral":[38,184],"administration":[39,185],"[14C]mobocertinib.":[41,187],"related":[43],"materials":[44],"were":[45],"highly":[46,190],"covalently":[47,191],"bound":[48,192],"to":[49,116,193],"plasma":[50,72,195],"proteins":[51],"such":[52],"human":[54,194,208],"serum":[55],"albumin.":[56],"The":[57,146],"mean":[58],"extraction":[59],"recovery":[60],"total":[62,86,203],"radioactivity":[63,89,206],"was":[64,77,125,131,189,211,229],"only":[65],"3.9%":[66],"for":[67,83,99,200],"6":[68],"individual":[69],"Hamilton":[70],"pooled":[71],"samples.":[73],"After":[74],"extraction,":[75],"most":[79],"abundant":[80],"component":[81],"accounting":[82],"7.7%":[84],"extracted":[87,204],"circulating":[88,205],"(TECRA)":[90],"supernatant.":[93],"Each":[94],"identified":[96],"metabolites":[97,124],"accounted":[98,199],"<10%":[100],"TECRA.":[102],"underwent":[104],"extensive":[105],"first-pass":[106],"fraction":[110,139],"dose":[113,228],"absorbed":[114],"estimated":[115],"be":[117],"approximately":[118,141,224],"91.7%.":[119],"Fecal":[120],"major":[127],"elimination":[128,149],"route.":[129],"mainly":[132,212],"eliminated":[133,213],"via":[134,214],"oxidative":[135,217],"88%":[142],"metabolized":[143],"by":[144,155,220],"CYP3A4/5.":[145],"other":[147,156],"minor":[148],"pathways":[150],"included":[151],"cysteine":[152],"conjugation,":[153],"CYPs,":[157],"renal":[159],"unchanged":[162],"mobocertinib.":[163],"Significance":[164],"Statement":[165],"manuscript":[167],"humans":[180],"proteins.":[196],"No":[197],"metabolite":[198],">10%":[201],"plasma.":[209],"CYP3A4/5":[215],"mediated":[216],"followed":[219],"fecal":[221],"91.7%":[225],"absorbed.":[230]},"counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":4}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2024-07-23T00:00:00"}